Studies show that compared to normal cells, epidermal growth factor receptor (EGFR) is overexpressed on the surface of NSCLC cells and, as such, is a suitable marker for active targeted therapy (Zhao et al., 2018). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.